BCR-ABL directed immunotherapy: A virtual reality?

Nearly ten years of research on the feasibility of specific immunotherapy t argeting the junctional regions of BCR-ABL has considerably increased our k nowledge of which MHC alleles might present BCR-ABL peptides, yet has faile d to provide us with definite proof of appropriate processing of the hybrid oncoprotein into such antigenic peptides. This paper intends to provide an overview of the current state of affairs as well as to delineate limitatio ns and future directions of this line of research.